BMC Cancer · 2015 · 27 citations · 30 references
MedicineOncologyUrologyGene ExpressionGenitourinary OncologyMolecular OncologyBiomarkers In Genitourinary CancerBiomarkers In Urologic OncologyBladder CancerKidney CancerMolecular Tumor ProfilingUrothelial CarcinomaBladder Cancer Recurrence BiomarkersCell Viability AssaysMicroarray AnalysisPrognostic Marker AssessmentPrognostic Marker EvaluationRadical NephroureterectomyTissue Microarray AnalysisUpper Tract Urothelial Carcinoma Biomarkers
BACKGROUND: To analyze the expression of karyopherin alpha 2 (KPNA2) in upper tract urothelial carcinoma (UTUC) and to investigate whether the KPNA2 expression provides additional prognostic information following radical nephroureterectomy (RNU). METHODS: A tissue microarray (TMA) containing samples from 176 patients with UTUC who underwent RNU at our institute was analyzed for KPNA2 expression using immunohistochemistry. KPNA2 expression in normal urothelial cell line and urothelial carcinoma cell lines was evaluated by western blot analysis. Using RNA interference in vitro, the effects of KPNA2 inhibition on cellular viability, migration and apoptosis were determined. RESULTS: KPNA2 expression was significantly upregulated in the UTUC samples compared with the adjacent normal urothelial tissues. High KPNA2 immunoreactivity was identified as a predictor of bladder recurrence (hazard ratio [HR]: 2.017, 95% CI 1.13-3.61, p = 0.018), poor disease-free survival (DFS, HR: 2.754, 95% CI 1.68-4.51, p = 0.001) and poor overall survival (OS, HR: 4.480, 95% CI 1.84-10.89, p = 0.001) for patients with UTUC after RNU. Furthermore, high KPNA2 immunoreactivity was independent of the conventional predictive factors in a multivariate analysis. Additional in vitro experiments revealed that KPNA2 expression was higher in urothelial carcinoma cell lines than in normal urothelial cell line. KPNA2 inhibition with a specific siRNA decreased cell viability and migration and increased apoptosis in urothelial carcinoma cell lines. CONCLUSIONS: KPNA2 is a novel independent prognostic marker for bladder recurrence, DFS and OS of UTUC patients who have undergone RNU. Moreover, these data suggest that KPNA2 may be a promising therapeutic target for UTUC.
30
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Juha Kononen, Lukas Bubendorf, Anne Kallionimeni et al. · Nature Medicine · 1998 · 4.1K citations
Vitaly Margulis, Shahrokh F. Shariat, Surena F. Matin et al. · Cancer · 2009 · 1.1K citations · Full text
European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update
Morgan Rouprêt, Marko Babjuk, Éva Compérat et al. · European Urology · 2013 · 451 citations
A Radu, G Blobel, Miranda S. Moore · Proceedings of the National Academy of Sciences · 1995 · 436 citations